دورية أكاديمية
Regimen for accelerated propranolol initial dosing (RAPID).
| العنوان: | Regimen for accelerated propranolol initial dosing (RAPID). |
|---|---|
| المؤلفون: | Huang CY; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Perman MJ; Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA., Yan AC; Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.; The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA. |
| المصدر: | Pediatric dermatology [Pediatr Dermatol] 2024 Jul-Aug; Vol. 41 (4), pp. 621-627. Date of Electronic Publication: 2024 Apr 17. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 8406799 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1470 (Electronic) Linking ISSN: 07368046 NLM ISO Abbreviation: Pediatr Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2010->: Hoboken, NJ : Wiley Original Publication: [Boston, MA] : Blackwell Scientific Publications, [1983- |
| مواضيع طبية MeSH: | Propranolol*/administration & dosage , Propranolol*/adverse effects, Humans ; Retrospective Studies ; Infant ; Female ; Male ; Hemangioma/drug therapy ; Child, Preschool ; Dose-Response Relationship, Drug ; Bradycardia/chemically induced ; Drug Administration Schedule ; Hypotension/chemically induced ; Adrenergic beta-Antagonists/administration & dosage ; Adrenergic beta-Antagonists/adverse effects ; Skin Neoplasms/drug therapy ; Infant, Newborn |
| مستخلص: | Background: Infantile hemangiomas are common vascular tumors in children. Propranolol has proven effective in treating infantile hemangiomas and while generally safe, has potential risk for more serious side effects of hypoglycemia, hypotension, bradycardia, bronchospasm, and cardiovascular or respiratory compromise. Current prescribing guidelines recommend initiating propranolol doses at 1 mg/kg/day, with up-titration to 2 mg/kg/day. This study aims to compare the incidence of adverse events in infants and children treated with propranolol initiated at 1 mg/kg/day versus being initiated directly at 2 mg/kg/day. Methods: A retrospective cohort study was conducted using medical records of patients receiving propranolol therapy for infantile hemangiomas between October 2018-March 2021 at the Children's Hospital of Philadelphia. Patients were categorized by initial propranolol dosage: 1 or 2 mg/kg/day. The primary outcome measures included parent-reported adverse events, hypotension (defined by the Pediatric Advanced Life Support criteria), and bradycardia (defined as <1st percentile for age) following propranolol initiation. Results: Out of the 244 patients identified, 123 were initiated at the 1 mg/kg/day dose, and 121 at the 2 mg/kg/day dose. There was no significant difference in the incidence of adverse events between the two groups (p = .057). Additionally, among patients initiated at 2 mg/kg/day, there were no significant differences in the incidence of age-related or weight-related adverse events for those younger than 2 months or those in the 1st or 2nd quartile for weight (p = .53). Conclusion: Infants and children initiated at 2 mg/kg/day did not demonstrate an increased incidence of adverse events associated with propranolol compared to those initiated at 1 mg/kg/day. These findings provide clinical evidence for the practice of accelerated propranolol initiation dosing. (© 2024 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC.) |
| References: | Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26(5):610‐614. doi:10.1111/j.1525‐1470.2009.00975.x. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168‐173. doi:10.1111/j.1525‐1470.2008.00626.x. Léauté‐Labrèze C, Hoeger P, Mazereeuw‐Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372(8):735‐746. doi:10.1056/nejmoa1404710. Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019;143(1):e20183475. doi:10.1542/peds.2018‐3475. Morimoto A, Ozeki M, Sasaki S, Baba N, Kuwano Y, Kaneko T. Severe hypoglycemia in propranolol treatment for infantile hemangiomas. Pediatr Int. 2022;64(1):e15278. doi:10.1111/ped.15278. Parker N, Flowers R, Vickery K, Stolfi A, Bugnitz C. Assessing the risk of hypoglycemia secondary to propranolol therapy for the treatment of supraventricular tachycardia in infants. Pediatr Cardiol. 2023;44(4):836‐844. doi:10.1007/s00246‐023‐03142‐9. Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128‐140. doi:10.1542/peds.2012‐1691. Hoeger PH, Harper JI, Baselga E, et al. Treatment of infantile haemangiomas: recommendations of a European expert group. Eur J Pediatr. 2015;174(7):855‐865. doi:10.1007/s00431‐015‐2570‐0. AHA, Association AH. Pediatric Advanced Life Support Provider Manual. American Heart Association, Incorporated; 2020 https://books.google.com/books?id=8qgmzgEACAAJ. Fleming S, Thompson M, Stevens R, et al. Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011;377(9770):1011‐1018. doi:10.1016/S0140‐6736(10)62226‐X. Putterman E, Wan J, Streicher JL, Yan AC. Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas. Pediatr Dermatol. 2019;36(4):471‐476. doi:10.1111/pde.13843. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta‐adrenoceptor‐blocking drugs. Prog Cardiovasc Dis. 1976;19(3):203‐234. doi:10.1016/0033‐0620(76)90016‐5. Perry JC, Garson A. The child with recurrent syncope: autonomic function testing and beta‐adrenergic hypersensitivity. J Am Coll Cardiol. 1991;17(5):1168‐1171. doi:10.1016/0735‐1097(91)90849‐5. Esler M, Zweifler A, Randall O, DeqUattro V. Pathophysiologic and pharmacokinetic determinants of the anti hypertensive response to propranolol. Clin Pharmacol Ther. 1977;22(3):299‐308. doi:10.1002/cpt1977223299. Filigheddu F, Reid JE, Troffa C, et al. Genetic polymorphisms of the β‐adrenergic system: association with essential hypertension and response to β‐blockade. Pharmacogenomics J. 2004;4(3):154‐160. doi:10.1038/sj.tpj.6500247. Serlin MJ, Orme MLE, Baber NS, Sibeon RG, Laws E, Breckenridge A. Propranolol in the control of blood pressure: a dose‐response study. Clin Pharmacol Ther. 1980;27(5):27‐592. doi:10.1038/clpt.1980.83. Takechi T, Kumokawa T, Kato R, Higuchi T, Kaneko T, Ieiri I. Population pharmacokinetics and pharmacodynamics of Oral propranolol in pediatric patients with infantile hemangioma. J Clin Pharmacol. 2018;58(10):1361‐1370. doi:10.1002/jcph.1149. Meyer‐Mueller C, Nicholson C, Polcari I, Boull C, Maguiness S. Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. Pediatr Dermatol. 2022;39(2):255‐259. doi:10.1111/pde.14933. Oulehri A, Baybay H, Elloudi S, Douhi Z, Mernissi FZ. Adverse effects of propranolol in a fulminant ulcerated infantile hemangioma. Our Dermatol Online. 2022;13:e19. doi:10.7241/ourd.2022e.19. Duncombe SL, Voss C, Harris KC. Oscillometric and auscultatory blood pressure measurement methods in children: a systematic review and meta‐analysis. J Hypertens. 2017;35(2):213‐224. doi:10.1097/HJH.0000000000001178. Püttgen KB, Hansen LM, Lauren C, et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol. 2021;85(2):345‐352. doi:10.1016/j.jaad.2020.04.013. Johansen ML, Mahendran G, Lawley LP. Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. Pediatr Dermatol. 2021;38(4):800‐805. doi:10.1111/pde.14651. |
| فهرسة مساهمة: | Keywords: infantile hemangioma; propranolol |
| المشرفين على المادة: | 9Y8NXQ24VQ (Propranolol) 0 (Adrenergic beta-Antagonists) |
| تواريخ الأحداث: | Date Created: 20240417 Date Completed: 20240722 Latest Revision: 20240722 |
| رمز التحديث: | 20240722 |
| DOI: | 10.1111/pde.15623 |
| PMID: | 38631683 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1525-1470 |
|---|---|
| DOI: | 10.1111/pde.15623 |